Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 19Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × CB-839 × Clear all
NCT02771626 2023-03-17

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Calithera Biosciences, Inc

Phase 1/2 Terminated
118 enrolled 18 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04265534 2022-09-21

KEAPSAKE

Calithera Biosciences, Inc

Phase 2 Terminated
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡